



## Biomarker and Translational Research in Oncology and Liver Diseases

Guest Editor:

**Prof. Dr. Matthias Ocker**

Medical Department, Division of Hematology, Oncology, and Cancer Immunology, Campus Charité Mitte, Charité University Medicine Berlin, 10117 Berlin, Germany

Deadline for manuscript submissions:

**closed (30 June 2023)**

### Message from the Guest Editor

Chronic liver diseases are a global medical burden. While some progress was made in identifying and validating diagnostic biomarkers, only a few advances have been achieved on predictive biomarkers that could also lead to novel treatment approaches. The focus on the inflammatory microenvironment in NASH, cirrhosis and HCC has further increased the complexity since novel approaches beyond T-cell targeting are maturing now. This also requires novel designs for clinical trials and the strong need to thoroughly characterize the disease and disease-modulating pathways in translational clinical and preclinical research and studies. It is important to highlight that translational studies go beyond the analysis of biomarkers but do also comprise bioinformatics, scheduling and clinical pharmacology applications.

In this Special Issue, we aim to summarize the current status and challenges of translational and biomarker research in preclinical and clinical research of liver diseases, including NAFLD, NASH, cirrhosis and HCC. We especially welcome papers focusing on artificial intelligence and translational approaches like modelling, molecular imaging or liquid biopsy technologies.

